Cargando…

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma

Over the past decade, therapies targeting the VEGF/VEGFR and mTOR pathways have served as the standard of care for the clinical management of renal cell carcinoma (RCC) patients. Albeit promising, these targeted drugs have attained only modest clinical benefits with limited prolonged progression-fre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Jingya, Wang, Xin, Tang, Boyun, Liu, Hongchun, Zhang, Minmin, Wang, Yueqin, Ping, Fangfang, Ding, Jian, Shen, Aijun, Geng, Meiyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010995/ https://www.ncbi.nlm.nih.gov/pubmed/29930727 http://dx.doi.org/10.7150/thno.23964

Ejemplares similares

Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type‐A Receptor 5 Kinases in Hepatocellular Carcinoma
por: Wang, Xin, et al.
Publicado: (2018)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

The Biology and Therapeutic Potential of the Src-YAP Axis in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2022)

SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis
por: Lamar, John M., et al.
Publicado: (2019)

Chromopeptide A, a highly cytotoxic depsipeptide from the marine sediment-derived bacterium Chromobacterium sp. HS-13-94
por: Zhou, Zhenfang, et al.
Publicado: (2015)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
por: XIAO, JUAN, et al.
Publicado: (2015)

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer
por: Chen, Danqi, et al.
Publicado: (2016)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells
por: Dosch, Austin R., et al.
Publicado: (2019)

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
por: Id Boufker, Hichame, et al.
Publicado: (2010)

Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling
por: WU, JIANGHONG, et al.
Publicado: (2013)

Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
por: Takiguchi, Eri, et al.
Publicado: (2017)

Wnt and Src signals converge on YAP‐TEAD to drive intestinal regeneration
por: Guillermin, Oriane, et al.
Publicado: (2021)

HOXC11–SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib
por: deBlacam, C, et al.
Publicado: (2011)

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
por: Scott, Aaron J., et al.
Publicado: (2017)

Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice
por: Lee, Dajeong, et al.
Publicado: (2020)

Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells
por: Chen, Bin, et al.
Publicado: (2015)

FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells
por: Zhang, Liping, et al.
Publicado: (2015)

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
por: Paris, Anaïs, et al.
Publicado: (2022)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation
por: Fu, Yang, et al.
Publicado: (2018)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
por: McKnight, Brooke N., et al.
Publicado: (2018)

The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
por: Appel, Camilla Kristine, et al.
Publicado: (2017)

Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging
por: Nobis, Max, et al.
Publicado: (2014)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021)

Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9
por: Jiang, Min, et al.
Publicado: (2013)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
por: Orive‐Ramos, Ana, et al.
Publicado: (2017)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

Involvement of NADPH oxidases in the Na/K‑ATPase/Src/ROS oxidant amplification loop in renal fibrosis
por: Zhang, Huimin, et al.
Publicado: (2023)

Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
por: Kadife, Elif, et al.
Publicado: (2019)

The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042
por: Hermida-Prado, Francisco, et al.
Publicado: (2019)

Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury
por: Macfarlane, James G., et al.
Publicado: (2020)

Author Correction: The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
por: Appel, Camilla Kristine, et al.
Publicado: (2019)

Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer
por: Wang, Tianshi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_moh7r22g6dfde1iod1esh60lbo